IN2012DN00624A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00624A
IN2012DN00624A IN624DEN2012A IN2012DN00624A IN 2012DN00624 A IN2012DN00624 A IN 2012DN00624A IN 624DEN2012 A IN624DEN2012 A IN 624DEN2012A IN 2012DN00624 A IN2012DN00624 A IN 2012DN00624A
Authority
IN
India
Prior art keywords
fatigue
treatments
diseases
prevention
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Moise A Khayrallah
Gary Bream
Stephen E Butts
Susan Marie Melnick
Duncan Taylor
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of IN2012DN00624A publication Critical patent/IN2012DN00624A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN624DEN2012 2009-06-22 2010-06-21 IN2012DN00624A (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
PCT/US2010/039313 WO2011005473A2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Publications (1)

Publication Number Publication Date
IN2012DN00624A true IN2012DN00624A (OSRAM) 2015-06-12

Family

ID=43429751

Family Applications (1)

Application Number Title Priority Date Filing Date
IN624DEN2012 IN2012DN00624A (OSRAM) 2009-06-22 2010-06-21

Country Status (13)

Country Link
US (5) US8741950B2 (OSRAM)
EP (1) EP2445490B1 (OSRAM)
JP (3) JP6095366B2 (OSRAM)
KR (3) KR102173587B1 (OSRAM)
CN (2) CN106727486A (OSRAM)
AU (1) AU2010270971B2 (OSRAM)
BR (1) BRPI1015233A2 (OSRAM)
CA (1) CA2765463C (OSRAM)
IN (1) IN2012DN00624A (OSRAM)
MX (1) MX2012000034A (OSRAM)
RU (1) RU2567801C2 (OSRAM)
TW (1) TWI453014B (OSRAM)
WO (1) WO2011005473A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201328689A (zh) 2005-06-08 2013-07-16 Sk Biopharmaceuticals Co Ltd 治療睡眠-覺醒病症之方法
RU2567801C2 (ru) * 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
MX2012005258A (es) 2009-11-06 2012-06-19 Sk Biopharmaceuticals Co Ltd El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad.
AU2010316172B2 (en) * 2009-11-06 2015-11-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
CA2853779C (en) * 2011-12-21 2016-04-26 Innobioscience, Llc Combined therapy with interferon and andrographolides for multiple sclerosis
KR102192554B1 (ko) 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 탈력발작의 치료
KR20210152011A (ko) * 2013-07-12 2021-12-14 에스케이바이오팜 주식회사 금연의 촉진
TW201919605A (zh) 2013-07-18 2019-06-01 南韓商愛思開生物製藥股份有限公司 肥胖之治療
WO2015067759A1 (en) * 2013-11-08 2015-05-14 Legacy Healthcare Ltd Method for the management of cancer and treatment of cancer comorbidities
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
SG11201901998WA (en) 2016-09-06 2019-04-29 Jazz Pharmaceuticals International Iii Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
JP7074750B2 (ja) 2016-10-06 2022-05-24 ジャズ ファーマスティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール化合物およびその使用
CN110139905B (zh) * 2016-12-30 2021-09-28 株式会社东进世美肯 涂层组合物及由此制备的薄膜
KR20240162165A (ko) 2017-06-02 2024-11-14 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
CA3071779A1 (en) 2017-07-31 2019-02-07 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
KR20240101826A (ko) * 2021-11-16 2024-07-02 액섬 몰타 엘티디. 인지 장애를 치료하기 위한 방법 및 조성물
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
AU4567597A (en) 1996-10-08 1998-05-05 Institute Of Child Health Mutant ciita molecule and uses thereof
JP4068154B2 (ja) * 1996-10-10 2008-03-26 エス ケー コーポレイション O―カルバモイル―フェニルアラニノール化合物とその薬剤学的に有用な塩及びその製造方法
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (ru) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
BRPI0518233A2 (pt) * 2004-10-28 2008-11-11 Sk Corp terapia adjunta para depressço
TW201328689A (zh) * 2005-06-08 2013-07-16 Sk Biopharmaceuticals Co Ltd 治療睡眠-覺醒病症之方法
CA2612672C (en) 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
BRPI0520451A2 (pt) 2005-07-26 2009-05-12 Janssen Pharmaceutica Nv métodos para tratamento de distúrbios associados a substáncias quìmicas
MX2009003926A (es) 2006-10-13 2009-06-26 Janssen Pharmaceutica Nv Composiciones de fenilalquilamino-carbamato.
RU2567801C2 (ru) * 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
MX2012005258A (es) 2009-11-06 2012-06-19 Sk Biopharmaceuticals Co Ltd El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad.
AU2010316172B2 (en) 2009-11-06 2015-11-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
KR102192554B1 (ko) * 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 탈력발작의 치료
JP6215740B2 (ja) * 2014-03-14 2017-10-18 本田技研工業株式会社 部品の締結構造

Also Published As

Publication number Publication date
JP2015214564A (ja) 2015-12-03
EP2445490A2 (en) 2012-05-02
KR102021075B1 (ko) 2019-11-04
US20180263950A1 (en) 2018-09-20
WO2011005473A9 (en) 2011-05-12
BRPI1015233A2 (pt) 2018-02-20
US20140243406A1 (en) 2014-08-28
KR102173587B1 (ko) 2020-11-04
US20200061017A1 (en) 2020-02-27
EP2445490A4 (en) 2019-10-23
RU2567801C2 (ru) 2015-11-10
RU2012101947A (ru) 2013-07-27
US8741950B2 (en) 2014-06-03
JP2018188450A (ja) 2018-11-29
JP6095366B2 (ja) 2017-03-15
TW201105320A (en) 2011-02-16
US20170000756A1 (en) 2017-01-05
EP2445490B1 (en) 2023-02-08
US10507192B2 (en) 2019-12-17
MX2012000034A (es) 2012-02-21
AU2010270971A1 (en) 2012-01-19
JP6368285B2 (ja) 2018-08-01
CA2765463A1 (en) 2011-01-13
AU2010270971B2 (en) 2015-08-20
TWI453014B (zh) 2014-09-21
WO2011005473A2 (en) 2011-01-13
US20120142769A1 (en) 2012-06-07
KR20120098578A (ko) 2012-09-05
KR20190105675A (ko) 2019-09-17
JP2012530779A (ja) 2012-12-06
US9999609B2 (en) 2018-06-19
CA2765463C (en) 2018-10-09
US9464041B2 (en) 2016-10-11
CN106727486A (zh) 2017-05-31
KR20170086710A (ko) 2017-07-26
CN102481274A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
IN2012DN00624A (OSRAM)
IN2012DN03883A (OSRAM)
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MY173616A (en) Compositions and methods for lowering triglycerides
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
MX2011007930A (es) Conjugados de insulina cristalina.
MY161495A (en) Virus like particle compositions and methods of use
IN2012DN02471A (OSRAM)
IN2012DN02081A (OSRAM)
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MY178905A (en) Prevention, treatment and diagnosis of p.gingivalis infection
TN2011000482A1 (en) Organic compounds and their uses
EA201001639A1 (ru) Композиции и способы их получения и применения
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX342947B (es) Tratamiento de diabetes tipo 2.
WO2013098416A3 (fr) Composes anti-douleur
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MY150931A (en) Substituted oxazolidinones and their use